Top line stable.
+0.9% YoY versus +0.7% prior. 3y CAGR +0.8%.
+0.9%We use cookies
MainRatios uses cookies for essential site functions. With your consent, we also use analytics cookies including session replay sampling (PostHog, Google Analytics) and advertising cookies (Google AdSense). You can reject non-essential cookies, including the "sale" or sharing of personal information under CCPA, and you may withdraw consent at any time (GDPR). See our Privacy Policy for details.
Healthcare · Market Cap: $13.7B
Fundamentals as of 2026-03-31
All analysis on this page is for educational purposes only and does not constitute financial advice. Fair values are model-based estimates. Always do your own research.
3 of 3 legendary models say AVOID SOLV.
What would legendary investors pay for SOLV?
These figures are not quotes or opinions from Buffett, Graham, Lynch or the other investors. They are our own estimates, computed by applying the intrinsic-value formulas each investor is known for to this company’s financials.
For educational purposes only. Not a recommendation to buy or sell securities.
Bottom line: SOLV is flagged as overvalued by 1 of 3 legendary models, with 0 BUY and 2 HOLD, but earns a C sector grade (54/100) in Healthcare. Whether the premium is justified depends on which lens you trust. Drill into the valuation breakdown and sector ranking for the full picture.
The Question
+0.9% YoY versus +0.7% prior. 3y CAGR +0.8%.
+0.9%Net margin 18.7% versus 5.8% prior (+12.9pp). Operating 26.2%.
18.7%P/E 9.9x — 8% above the 5y median of 9.2x. Forward 11.5x signals EPS contraction next year.
9.9xYes — Solventum Corporation's 28.8% ROE ranks above the S&P 500 median, and D/E 1.84 stays within healthy bounds.
Financial story
Yes — Solventum Corporation's 28.8% ROE shows strong capital efficiency, and its 1.84 debt-to-equity stays within healthy bounds.
How does SOLV compare?
See exactly where SOLV ranks
Sign in to unlock the full sector ranking — free.
Sign in to see the rankingSOLV sits at #36 in Healthcare with a C grade (54/100).
0 of 3 legendary investor models rate SOLV a BUY. Fair value estimates and full investor breakdown are in the valuation tab.
Average fair value across qualifying models: $72. See the per-investor fair-value table in the valuation tab.
SOLV trades at 9.0x earnings. Sector context and per-investor signals are in the valuation tab.
SOLV and COO differ on P/E, ROE, and revenue growth. See the full SOLV vs COO compare matrix.
Buffett, Greenblatt, and Munger evaluate SOLV against their respective frameworks. Per-model fair value and reasoning are in the valuation tab.
SOLV's P/E ratio is 9.0x. 5-year P/E history is in the financials tab.